The 5-HT\textsubscript{3} receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat

C M Kozlowski, A Green, D Grundy, F M Boissonade, C Bountra

Abstract

Background—Noxious intestinal distention elicits a reflex depressor response in the sodium pentobarbitone anaesthetised rat, which can be used as an index of visceral nociception. 5-HT\textsubscript{3} receptor antagonists inhibit this reflex. Repeated colorectal distention (CRD) induces Fos-like immunoreactivity (Fos-LI) in the rat spinal cord.

Aims—To examine the effect of the 5-HT\textsubscript{3} receptor antagonist alosetron on the depressor response to CRD, and on Fos expression in the lumbosacral spinal cord.

Methods—Male rats were anaesthetised with sodium pentobarbitone, and mean arterial blood pressure monitored during repeated colorectal balloon inflation before and after treatment with alosetron or saline. Rats anaesthetised with urethane and treated with alosetron or saline underwent a repeated CRD paradigm, after which the lumbosacral spinal cord was removed and processed for visualisation of Fos-LI.

Results—CRD elicited reproducible, volume dependent falls in arterial blood pressure, and repeated distention-effect curves were constructed. Alosetron (1–100 µg/kg intravenously) inhibited the depressor response to CRD in a dose related manner, with an ID\textsubscript{50} value of 3.0 µg/kg. Following repeated CRD, numbers of Fos-LI neurones were significantly increased to 1246 (total in 12 sections at 120 µm intervals from L6 to S1) compared with 49 in sham distended animals. Pre-treatment with alosetron (100 µg/kg) significantly reduced numbers of Fos-LI neurones to 479.8.

Conclusion—The 5-HT\textsubscript{3} receptor antagonist alosetron inhibits the depressor response to CRD in a potent and dose dependent manner. It also inhibits CRD induced Fos-LI in the spinal cord. These results suggest that 5-HT\textsubscript{3} receptors are involved in visceral nociceptive transmission, perhaps located on primary afferent or spinal neurones.

In man, distention of the gastrointestinal tract elicits visceral pain, as well as sensations including fullness and discomfort.\textsuperscript{1,2} In healthy subjects, visceral pain occurs in response to potentially tissue damaging distention pressure; however, the irritable bowel syndrome (IBS) has been described as a hypersensitivity of the gut, as many patients show reduced thresholds to pain and associated sensations in response to rectal balloon distention, which is not due to altered compliance.\textsuperscript{3} Recent studies have shown that 5-HT\textsubscript{3} receptor antagonists may modify gut sensation in patients with IBS. Alosetron has been reported to reduce pain scores significantly, and to increase rectal compliance in patients with IBS.\textsuperscript{4} Granisetron has also been reported to reduce rectal sensitivity in patients with IBS; although ondansetron seems to be ineffective at reducing pain scores in similar studies.\textsuperscript{10,11}

In animals, noxious intestinal distention elicits a range of pseudoaffective responses including vasomotor, visceromotor, and respiratory responses,\textsuperscript{12–15} which can be used as an index of visceral nociception. The vasomotor response consists of a transient increase or decrease in arterial blood pressure, which is dependent on state and type of anaesthesia.\textsuperscript{16} This reflex is abolished by neonatal or perineural capsaicin,\textsuperscript{17,18} and is blocked by morphine in a naloxone reversible manner.\textsuperscript{19} Noxious intestinal distention also elicits an aversive response in conscious rats, as measured in a passive avoidance paradigm.\textsuperscript{20} Thus, intestinal distention can be considered to be an appropriate stimulus for studies of visceral nociception.

The immediate early gene c-fos is expressed in discrete areas of the central nervous system following chemical (cyclophosphamide, acetic acid, formalin, capsaicin) or mechanical (distention, ligature) visceral stimulation.\textsuperscript{21–23} Repetitive colorectal distention (CRD) induces c-fos expression in rat spinal cord, the number of Fos-like immunoreactive neurones increasing with stimulus intensity.\textsuperscript{24} Numbers of Fos-like immunoreactive nuclei are greatest in the lumbosacral spinal segments following CRD, which corresponds to afferent projection from the pelvic nerve.\textsuperscript{25} Systemic morphine has been shown to attenuate c-fos expression in the rat spinal cord; pseudoaffective reflex.

Keywords: colorectal distention; alosetron; Fos; 5-HT\textsubscript{3}; spinal cord; pseudoaffective reflex

Abbreviations used in this paper: CRD, colorectal distention; Fos-LI, Fos-like immunoreactive; IBS, irritable bowel syndrome.
spinal cord following noxious colorectal distention.\textsuperscript{20}

In animal studies, a number of 5-HT\textsubscript{3} receptor antagonists have been reported to inhibit the vasomotor response to noxious intestinal distention.\textsuperscript{27, 28} In the pentobarbital anaesthetised rat, ondansetron, granisetron, and tropisetron have been shown to inhibit dose dependently volume related hypotensive responses that are also sensitive to inhibition by morphine, in a naloxone sensitive manner.\textsuperscript{29} In the present study, we have extended these studies to investigate the effect of the potent and selective 5-HT\textsubscript{3} receptor antagonist alosetron,\textsuperscript{30} and we also report the effect of alosetron on repetitive noxious CRD evoked spinal \textit{c-fos} in the urethane anaesthetised rat. Thus we aim to establish a mechanism of action of 5-HT\textsubscript{3} receptors specific to visceral nociceptive neurotransmission. A preliminary account of this work has been presented in abstract form.\textsuperscript{31}

Methods

All experiments were performed using male Wistar rats (220–340 g) with food and water ad libitum. All procedures were carried out in accordance with "Principles of laboratory animal care" (NIH publication No. 85-23) and Home Office guidelines (Animals (Scientific Procedures) Act 1986).

COLORECTAL DISTENTION—DEPRESSOR RESPONSE

Twenty nine rats were anaesthetised with sodium pentobarbitone (60 mg/kg intraperitoneally; 3–5 mg/kg intravenously). The trachea, right external jugular vein, and carotid artery were cannulated. The carotid cannula was connected to a chart recorder via a blood pressure transducer for continuous measurement of blood pressure. Body temperature was kept constant at 36–37°C using a homeothermic blanket. A 1 cm long latex balloon was inserted intrarectally so that the tip of the balloon was 2 cm from the anal verge. The balloon was connected via a double barrelled cannula to a pressure transducer, and to a saline filled syringe for inflation/deflation of the balloon (the cannula was secured to the base of the tail with tape). The animals were left for 20 minutes, in order to obtain a stable recording baseline. The balloon was rapidly inflated with increasing volumes of saline (0.5–2.5 ml) for 30 seconds at five minute intervals and resultant blood pressure changes recorded. The value taken was the maximum decrease in mean arterial pressure obtained during the 30 second distention period. Three distention-response curves were constructed in this manner, allowing 10 minutes between successive curves. Alosetron (1–100 \textmu g/kg) or saline was administered 10 minutes prior to commencement of the third curve. A single dose only was tested in each animal.

COLORECTAL DISTENTION—SPINAL \textit{c-fos} EXPRESSION

A total of 19 rats in four groups were included in this study: control CRD with intravenous saline (n=5), alosetron (30 \textmu g/kg; n=5), alosetron (30 \textmu g/kg; n=5), and sham distended (n=4). Rats were anaesthetised with urethane (1.5 g/kg intraperitoneally). The trachea was intubated and the right external jugular vein was cannulated for drug administration. A 4 cm long latex balloon was inserted intrarectally until the tip of the balloon was 5 cm from the anal verge. The balloon was connected via a cannula to a barostat (Bioengineering, GlaxoWellcome Research and Development), and was inflated to 80 mm Hg for 30 seconds, every two minutes for a total of 120 minutes. In control (sham distended) animals, the balloon was not inflated. Within 30 minutes following the end of the distention period, the rats were perfused intracardially with 150 ml phosphate buffered saline followed by 300 ml neutral buffered formalin (Pioneer Research Chemicals Ltd).

The lumbosacral spinal cord (L4–S2) was removed and postfixed in fresh fixative for four hours at 4°C, then transferred to 30% sucrose in 0.1 M phosphate buffer overnight, again at 4°C for cryoprotection. Sections (40 \textmu m) were cut on a freezing microtome; every fourth section was collected. Sections were washed in PBS and incubated for \textit{Fos-like immunoreactivity} using the avidin-biotin technique, following a method similar to that described previously by Boissonade \textit{et al.}\textsuperscript{31} Briefly, following preincubation with 10% normal rabbit serum (NRS) diluted in phosphate buffered saline (PBS) containing 0.2% Triton (PBST) for one hour, sections were incubated in an antibody raised in sheep against \textit{Fos} (anti-\textit{Fos} polyclonal antibody, 1/5000, Genosys Biotechnologies Inc., Cambridge, UK; diluted in PBST containing 5% NRS) for 44–48 hours at 4°C. The sections were rinsed, and incubated for 30 minutes in a solution containing biotinylated rabbit antisheep IgG (1/300, 30 minutes; Vector Laboratories Inc., Burlingame, California, USA), then incubated with the avidin-biotin complex (Vectastain Elite kit, Vector Laboratories Inc.). The reaction product was visualised using diaminobenzidine solution containing H\textsubscript{2}O\textsubscript{2} and nickel chloride (DAB substrate kit, Vector Laboratories Inc.); the sections were then mounted on gelatin coated glass slides, dehydrated, and coverslips applied. To assess antibody specificity, diluted \textit{Fos} antibody was preincubated with \textit{Fos} peptide (10 nmol/ml; Genosys; for 24 hours at 4°C) prior to the procedure above. In addition, incubation with the primary antibody was omitted for some sections. In either case, no significant staining was observed.

Numbers of \textit{Fos}-like immunoreactive (\textit{Fos-LI}) nuclei were counted in 12 consecutive sections across the L6–S1 border as identified by morphology; the total number of \textit{Fos-LI} nuclei in 12 sections was used for subsequent data analysis. The grey matter was divided into four morphology; the total number of \textit{Fos-LI} nuclei were counted in 12 sections was used for subsequent data analysis. The grey matter was divided into four sections across the L6–S1 border as identified by morphology; the total number of \textit{Fos-LI} nuclei in 12 sections was used for subsequent data analysis. The grey matter was divided into four regions, similar to those described previously\textsuperscript{32} for assessing regional distribution of \textit{Fos-LI} nuclei (see fig 1). Images of the spinal sections were taken using an image analysis package (Leica Q600 running QWIN software; Leica UK Ltd, Milton Keynes, UK).
COMPOUNDS
Alosetron (2,3,4,5 tetrahydro-5-methyl-2-[5-methyl-1-H-imidazol-4-yl-methyl]-1H-pyrido[4,3-b]indol-1-one maleate; GlaxoWellcome) was dissolved in saline (0.9%, wt/vol sodium chloride) and was administered intravenously 10 minutes prior to the onset of the test procedure in both experimental groups (600 µl dose volume). Urethane was purchased from Sigma and dissolved in saline (33% wt/vol).

DATA AND STATISTICAL ANALYSIS
Results are given as mean (SEM) from n observations. For the depressor response experiments, the ID₅₀ for alosetron was calculated as the dose required to inhibit the response to a 1.5 ml distention by 50% (geometric mean with 95% confidence limits), and statistical significance was determined using Student’s paired t test. In the immunocytochemistry study, significance was determined using one way analysis of variance (ANOVA) followed by Dunnett’s post hoc test for multiple comparisons. In both cases, p<0.05 was considered significant.

Results
DEPRESSOR RESPONSE
The pentobarbitone anaesthetised rats displayed a mean arterial blood pressure of 108.3 (6.1) mm Hg (n=12). CRD (0.5–2.5 ml) elicited volume dependent falls in mean arterial blood pressure which were rapid in onset, and persisted for the duration of the distention period, despite some reduction (10–15%) in intraballoon pressure, returning to control.
values within two minutes after the distention was stopped. Some animals (26% in this study) did not display a depressor response to CRD; these animals were excluded. Preliminary studies showed that sequential distention-effect curves could be constructed, the second and third of which were highly reproducible (fig 2). In all subsequent experiments, the first distention-effect curve acted as a primer, the second as control, and the third curve was constructed following drug administration.

The 5-HT3 receptor antagonist alosetron (1–100 µg/kg) inhibited the depressor response to colorectal distention in a dose related manner (fig 3). The response to 1.5 ml CRD was significantly inhibited at doses of 3–100 µg/kg (p<0.05), giving an ID50 of 3.0 µg/kg (0.4–9.3). At 10 µg/kg, alosetron reduced the response to 1.5 ml CRD to 3.3 (4.4) mm Hg compared with 21.8 (1.7) mm Hg control response (p<0.05, n=5). There was no further inhibition at doses up to 100 µg/kg (4.2 (2.4) mm Hg compared with 22.9 (2.3) mm Hg control response; p<0.05, n=6). Reduction of the response to 2.5 ml distention was greatest at 100 µg/kg (15.4 (6.1) mm Hg versus 27.1 (2.1) mm Hg control response; p<0.05, n=6). Alosetron had no effect on basal blood pressure (112.4 (6.8) mm Hg at 100 µg/kg versus 108.3 (6.1) mm Hg in control animals; n=6).

**FOS EXPRESSION**

Repetitive CRD significantly increased bilateral expression of Fos-LI compared with sham distended animals (from 49 (24) to 1246 (146); p<0.05, n=4–5). This expression was located in discrete areas of the spinal grey mat-

---

**Figure 4** Alosetron reduces the number of Fos-like immunoreactive (Fos-LI) nuclei (in 12 sections across L6–S1) evoked following 2 h (80 mm Hg, for 30 s every 120 s) repeated colorectal distention. *p<0.05; **p<0.01, significant reduction of Fos-LI.

**Figure 5** Representative bitmap images illustrating distribution of Fos-like (Fos-LI) immunoreactivity in all treatment groups: (A) sham distended; (B) control colorectal distention (CRD); (C) CRD/alosetron, 30 µg/kg; (D) CRD/alosetron 100 µg/kg. Horizontal scale bar, 150 µm; arrows indicate examples of Fos-LI nuclei.
ter (fig 1): Fos-LI nuclei were located in superficial laminae I and II of the spinal cord (area 1, 27.6% of total), lateral laminae V and VI, including the intermediolateral horn (area 3, 31.3%), and the area surrounding the central canal (medial lamina VII and X; area 4, 30.2%). There were fewer Fos-LI nuclei in laminae III and IV (area 2, 10.9%), and staining in the ventral horn region of areas 3 and 4 was relatively sparse. In sham distended animals, total numbers of Fos-LI were too low to assess differences in regional distribution.

In animals pretreated with 100 µg/kg alosetron, total numbers of Fos-LI nuclei were significantly reduced (479.8 (122); p<0.05, n=5). At a lower dose (30 µg/kg), alosetron did not significantly reduce the total number of Fos-LI nuclei (993 (89), n=5). Regionally, alosetron inhibited Fos-LI in specific areas of the spinal cord (see fig 4), with reductions of 56% in area 1, 63% in area 3, and 68% in area 4 (100 µg/kg, p<0.05). There was no significant inhibition of Fos-LI in area 2. At 30 µg/kg, alosetron did not significantly reduce numbers of Fos-LI nuclei in any region, although there was a reduction of 35% in area 1. Figure 5 shows the distribution of Fos-LI nuclei in control and drug treated animals.

Discussion
We have shown that responses to CRD using two experimental paradigms are blocked by the 5-HT₃ receptor antagonist alosetron. In the pentobarbitone anaesthetised rat, noxious CRD elicits reproducible depressor responses, consistent with previous studies in both the small and large intestine.⁴⁻⁵ We have also shown that reproducible distention-effect curves obtained in this study can be used to assess drug effects. Of the animals tested, 74% displayed a vigorous depressor response to CRD, which is similar to previous findings.¹ ² In the present study, the response parameters were somewhat dependent on the depth of anaesthesia. In urethane anaesthetised rats, however, where such reflexes are reported to be unaffected by anaesthetic levels, a similar proportion of animals do not display a depressor response to CRD, thus levels of anaesthetic probably do not account for the majority of non-responders in the present study.

Alosetron is a potent and selective 5-HT₃ receptor antagonist, with a duration of action of several hours in the rat.²⁹⁻³² It potently inhibited the depressor response to CRD, with an ID₅₀ of 3 µg/kg. The 1.5 ml distention volume at which the ID₅₀ is calculated was chosen as it produces a submaximal vasomotor response, of a similar magnitude to that evoked by 60–80 mm Hg barostat inflation (unpublished observations), and thus is well above the nociceptive threshold of approximately 30 mm Hg. Therefore the effects of alosetron at this distention volume are likely to be antinociceptive. In a similar study, the 5-HT₃ receptor antagonists ondansetron, tropisetron, and granisetron were shown to be approximately equipotent at inhibiting the depressor response to CRD.²⁸ They were 5–10 fold less potent than alosetron in the present study; bell shaped dose-response relations obtained with certain 5-HT₃ receptor antagonists may, however, result in underestimation of their potency.²⁸ Alosetron did not display a bell shaped dose-response relation in this study, with stable inhibitory effects between 10 and 100 µg/kg. In other studies, systemic 5-HT₃ receptor antagonists block the vasomotor response to distention of the duodenum and colorectum;²⁷¹ these data are therefore consistent with previous findings. Continuous monitoring of intraballoon pressure allowed the calculation of colorectal compliance from pressure-volume relations. Alosetron did not seem to affect colorectal compliance significantly in this study (unpublished observations), although this method may not be as sensitive as a barostat for detecting very small changes, as alosetron has been shown to increase compliance in studies with IBS.⁶⁻⁸ Any such effects of alosetron on compliance in the present study would not be sufficient to account for its effect on the vasomotor response to CRD.

Noxious CRD also induced expression of the proto-oncogene c-fos in the lumbosacral spinal cord of urethane anaesthetised rats. Fos-LI nuclei were found bilaterally, mainly in laminae I, II, lateral V and VI, VII and X. A similar distribution pattern has been noted previously,¹⁰⁻¹¹ which correlates with the termination sites of pelvic nerve afferents.¹²⁻¹³ The number of Fos-LI nuclei in the present study was lower than that reported in other studies, with 1246 (146) Fos-LI nuclei in 12 sections across the L₆–S₁ border, compared with over 300/section.¹² This difference may be explained by use of urethane anaesthesia in the present study, compared with halothane sedation in previous studies.

Alosetron (100 µg/kg) significantly reduced total numbers of Fos-LI in response to repetitive CRD, which is similar to previous findings.¹ ² In the present study, compared with halothane sedation in previous studies.

Alosetron (100 µg/kg) significantly reduced total numbers of Fos-LI in response to repetitive CRD, which is similar to previous findings.¹ ² In the present study, compared with halothane sedation in previous studies.

Alosetron (100 µg/kg) significantly reduced total numbers of Fos-LI in response to repetitive CRD, which is similar to previous findings.¹ ² In the present study, compared with halothane sedation in previous studies.
staining (amount of Fos-like protein) certainly do occur, but were not examined in the present study. This may also explain the steep dose-response curve obtained with alosetron, with a profound effect at 100 µg/kg, but no effect at 30 µg/kg. Different anaesthetics were used for the two experimental procedures, but it is unlikely that this had a major impact on the apparent efficacy of alosetron.

Induction of c-fos is thought to be largely indicative of c-fibre afferent activation, although Fos-LI occurs in response to both noxious and innocuous visceral and joint stimulation. The majority of afferents innervating the colon are c-fibres, most of which show a graded response to increasing stimulus intensity. Therefore, induction of Fos-LI in this model does not necessarily represent induction of nociceptive pathways. Traub et al have reported that the opiate analgesics, morphine and tramadol, reduce CRD evoked spinal Fos-LI in both superficial and deep laminae. Their study provides some evidence that a significant proportion of the CRD evoked Fos-LI results from noxious stimulation. Furthermore, many dorsal horn neurones in the spinal cord, the trigeminal nucleus by 5-HT3 receptor antagonists following noxious chemical stimulation, and dorsal root ganglion neurones. A large proportion of the spinal neurones are located on the central terminals of afferent neurones, many of which are capsaicin sensitive. The present finding that deep as well as superficial laminar expression of c-fos was suppressed by alosetron, is not inconsistent with these data. Visceral afferent neurones have collaterals extending into deep as well as superficial laminae, although these neurones comprise a small proportion of the total number of afferents entering the spinal cord. Furthermore, many dorsal horn neurones in deeper laminae receive indirect input from superficial neurones; either these interneurones or the afferents terminating on them may express 5-HT1 receptors. Further evidence to support a role for 5-HT1 receptors in nociceptive processing includes the inhibition, by granisetron, of CRD induced c-fos immunoreactivity in the nucleus of the solitary tract, and the reduction of c-fos immunoreactivity in the trigeminal nucleus by 5-HT1 receptor antagonists following noxious chemical stimulation of the rat nasal mucosa. 5-HT1 receptors are also found within the enteric nervous system of the gut, and are known to regulate gastrointestinal motility. Alosetron has been reported to normalise gut transit following sensitisation with egg albumin in rats, and to increase colonic compliance in patients with IBS. Alosetron and Rademaker, however, have suggested that the site of action against distention evoked reflexes is not within the peripheral organ, as the 5-HT1 receptor antagonist ICS 205 930 inhibits the depressor response to ileal distention, but has no effect on the concurrent increased firing in afferent dorsal root filaments. It is also worth noting that on vagal afferents innervating the stomach and small intestine, 5-HT1 receptors are associated with mucosal chemoreceptors rather than mechanoreceptors responsive to distention. Alosetron has also been reported to inhibit the vasomotor response to CRD in dogs following intracerebroventricular injection, suggesting a central site of action.

In summary, these studies show that alosetron modulates visceral nociceptive neurotransmission in the rat, illustrated by a potent inhibition of the reflex depressor response to colorectal distention, and a reduction in numbers of Fos-LI nuclei in the spinal cord following repeated CRD. There is considerable anatomical and functional data to support a role for 5-HT1 receptors in visceral nociceptive processing. The site(s) of action of alosetron were not established in the present study, but could be at the level of the enteric or primary sensory neurone, or via spinal or supraspinal neuronal circuits concerned with the modulation of nociceptive transmission. Based on these data, in addition to recent studies indicating that alosetron decreases symptoms of abdominal pain in patients with irritable bowel syndrome, alosetron may be of potential use in the treatment of visceral pain conditions.

3 Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome Gut 1973;14:125–32.
19 Jin GR, Rao ZR, Shi JW. Visceral nociceptive transmission induced expression of Fos protein in medullary catecholaminergic neurones projecting to nucleus accumbens in the rat: a study with triple labeling method of HRP tracing.
combined with Fos and TH immunohistochemistry. 

20 Cruz F, Avilén A, Coimbra A. Desensitisation follows exci-
tation of bladder primary afferents by intravesical capsa-
isin, as shown by c-fos activation in the rat spinal cord. 

21 Clermont CI, Keay KA, Owler BK, et al. Common patterns of
increased and decreased fos expression in midbrain and
pons evoked by noxious deep somatic and nonnoxious visceral

22 Fitch GK, Weiss ML. Unilateral ligature induces Fos expres-

distension increases fos expression in the lumbarosacral
spinal cord and activates sacral parasympathetic NADPH-

the lumbarosacral spinal cord following noxious and non
noxious colorectal distension in the rat. Pain 1992; 49:393–
403.

lulation of visceral afferent pathways in the pelvic nerve
increases c-fos in the rat lumbarosacral spinal cord. 

26 Traub RJ, Stitt S, Gebhart GF. Attenuation of c-Fos expres-
sion in the rat lumbarosacral spinal cord by morphine or tr
extend 
infusion of the novel selective 5-HT3 receptor antago-

27 Moss HE, Sanger GJ. The effects of granisetron, ICS 205–
930 and ondansetron on the visceral pain reflex induced by

28 Scott CM, Green A, Gale JD, et al. The effect of 5-HT3
receptor antagonists on the depressor response to colorec-
tal distension in the anaesthetised rat. Br J Pharmacol
1991; 104:259P.

29 Kilpatrick GJ, Hagan RM, Butler A, et al. GR87759, a
potent and selective antagonist of 5-HT3 receptors. 
Br J Pharmacol 1991; 100:210P.

30 Scott CM, Grundy D, Boissonade FM, et al. Alosetron
inhibits the colorectal distension-evoked depressor re-
sponse and spinal c-fos expression in the anaesthetised rat

31 Boissonade FM, Shurley KA, Davison JS. Fos expression in
ferret dorsal vagal complex after peripheral emetic stimuli. 

32 Clayton NM, Sargent R, Butler A, et al. The pharmacologi-
cal properties of the novel selective 5-HT3 receptor antagon-
ast, alosetron, and its effects on normal and perturbed
small intestinal transit in the fasted rat. Neurogastroenterol

33 Baner SE, Carter M, Sanger GJ. 5-Hydroxytryptamine 3
receptor antagonism modulates a nonnoxious visceral

34 Nadelhaft I, Booth AM. The location and morphology of
preganglionic neurons and the distribution of visceral affer-
ents from the rat pelvic nerve: a horseradish peroxidase stud-

35 DeGroat WC. Neuropeptides in pelvic afferent pathways. 

36 Bird LA, DeGroat WC. Induction of c-fos expression in
spinal neurons by nociceptive and non nociceptive stimula-

37 Hunt SP, Pini A, Evans G. Induction of c-fos-like protein in
spinal cord neurons following sensory stimulation. Nature

38 Sengupta NJ, Gebhart GF. Characterization of mechano-
sensitive pelvic nerve afferent fibres innervating the colon

autoradiographic mapping of 5-HT3 receptors in the rat
CNS using [3H]zolofazodacpride and [3H]zacopride as 

40 Tecott LH, Marić AV, Julius D. Nervous system distribu-
tion of the serotonin 5-HT3 receptor mRNA. Proc Natl

41 Kia HK, Miquel MC, McKernan RM, et al. Localization of
5-HT3 receptors in the rat spinal cord: immunohistoches-

42 Laporte AM, Pattacini CM, Lombard MC, et al. Effects of
dorsal rhizotomy and selective lesion of serotonergic and
noradrenergic systems on 5-HT1A, 5-HT1B and 5-HT3
receptors in the rat spinal cord. J Neural Transm Gen Sect
1995; 100:207–23.

43 Pierce PA, Xie GX, Levine JD, et al. 5-hydroxytryptamine
receptor subtype messenger RNAs in rat peripheral sensory
and sympathetic ganglia: a polymerase chain reaction

44 Hanson M, Gallissot MC, Menard F, et al. 5-HT3 receptor
binding sites are on capsaicin-sensitive fibres in the rat

45 Mennikes H, König M, Arnold R. Colonic distension-
induced c-fos expression in the nucleus tractus solitarii
(NTS) is diminished by the 5-HT3 receptor antagonist

and 5-HT3 receptor antagonists reduce c-fos expression in
the trigeminal nuclear complex following nonnoxious chemical
stimulation of the rat nasal mucosa. Brain Res 1995; 676:
334–42.

47 Clayton NM, Gale JD, Bountra C, et al. Normalisation of
perturbed small bowel transit by alosetron, a 5-HT3 recep-

48 Cramer WCM, Rademaker B. 5-HT3 receptors and visceral
nociception: involvement and localisation. Dig Dis Sci

49 Eastwood C, Hillsley K, Grundy D. Sub-populations of
small intestinal mucosal afferents identified by their sensi-
tivity to CCK, 5-HT and opiates. Neurogastroenterol Motil
1995; 7:256.

50 Muir A, Lawson C, Clary EM, et al. Central modulation of
rectal distension-induced blood pressure changes by
alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci
The 5-HT₃ receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat
C M Kozlowski, A Green, D Grundy, F M Boissonade and C Bountra

Gut 2000 46: 474-480
doi: 10.1136/gut.46.4.474

Updated information and services can be found at: http://gut.bmj.com/content/46/4/474

These include:

References
This article cites 49 articles, 2 of which you can access for free at: http://gut.bmj.com/content/46/4/474#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/